London, United Kingdom
Ro5, founded in 2018 and headquartered in the United Kingdom, is making significant strides in the intersection of AI, Biotechnology, and Pharmaceutical industries. With its compelling slogan, "Bioactivity. De Novo Drug Discovery. ADMET. Knowledge Graph.", Ro5 positions itself as a pioneering force in making AI accessible to drug discovery researchers.
Leveraging five years of experience, Ro5 offers an innovative software platform tailored for real-world challenges, enhancing the productivity of pharmaceutical companies and Contract Research Organizations (CROs) by enabling data-driven decisions and accelerating research. The company boasts a growing portfolio of scientific achievements with 3 papers and 13 awarded patents, demonstrating its thought leadership and innovation capacity.
As of the latest update, Ro5 secured a Seed Round investment on 01 February 2020, which substantiates investor confidence in its potential to transform digital workflows within the industry. Ro5 is poised for further growth and seeks to attract investors with interest in AI-driven healthcare solutions.
